| Name | Title | Contact Details |
|---|
Considine & Associates is a Laguna Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Comfort Keepers is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dayton, OH. To find more information about Comfort Keepers, please visit www.comfortkeepers.com
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Providence Medical Technology is a privately held medical device company developing innovative solutions addressing the $1 billion worldwide cervical spine market. We are commercializing the DTRAX platform of differentiated cervical implants and instruments to treat cervical degenerative disease through indirect decompression and fusion.